A Randomized, Masked (Reading Center), Prospective Pilot Study of the Safety and Effectiveness of the EyeGate Ocular Bandage Gel, a 0.75% Crosslinked Hyaluronic Acid Applied Topically, Versus a Bandage Contact Lens for Acceleration of Re-epithelialization of Large Corneal Epithelial Defects in Patients Having Undergone Photorefractive Keratectomy (PRK).
Not yet recruiting
Phase of Trial: Phase I/II
Latest Information Update: 07 Aug 2017
At a glance
- Drugs Hyaluronic acid (Primary)
- Indications Corneal disorders
- Focus Therapeutic Use
- Sponsors EyeGate Pharma
- 07 Aug 2017 According to a EyeGate Pharmaceuticals media release, the company anticipates top-line data by the end of this year.
- 07 Aug 2017 According to a EyeGate Pharmaceuticals media release, the company submitted investigational device exemption (IDE) filing of EyeGate ocular bandage gel (EyeGate OBG) for the acceleration of re-epithelialization of large corneal epithelial defects in patients having undergone photorefractive keratectomy (PRK).
- 25 Jul 2017 Planned End Date changed from 31 Aug 2017 to 31 Dec 2017.